Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | F7 | P08709 | 13/20 | 0.53 |
| ▸ | F3 | P13726 | 12/20 | 0.53 |
| ▸ | F10 | P00742 | 11/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 11/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882716 | 0.93 | F7 (0.54) | ITGB3ITGA2BF7F3F10 | |
| SCHEMBL5882922 | 0.87 | MAPK9 (0.46) | ITGB3ITGA2BPLAUMAPK9NPC1 | |
| SCHEMBL7328683 | 0.83 | RAB9A (0.59) | MAPK9NPC1RAB9ACASP3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8113591 | 0.83 | F2 (0.63) | ITGB3ITGA2BF7F3F10 | |
| Hydrochloric Acid SCHEMBL7148044 | 0.83 | F2 (0.63) | ITGB3ITGA2BF7F3F10 | |
| SCHEMBL5881900 | 0.81 | F7 (0.55) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882819 | 0.80 | PTGS1 (0.47) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL31527696 | 0.80 | EDNRA (0.48) | ITGB3ITGA2BMAPK9 | |
| SCHEMBL5882351 | 0.80 | SMN1; SMN2 (0.46) | MAPK9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5883122 | 0.78 | F7 (0.57) | F7F3F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ITGB3 4814/4885ITGA2B 4812/4885F7 1019/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ITGB3 4814/4885ITGA2B 4812/4885F7 1019/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | ITGB3 4814/4885ITGA2B 4812/4885F7 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.